First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Patients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-escalation study, in which CRLX101 was administered intravenously over 60 min among two dosing schedules, initially weekly at 6, 12, and 18 mg/m(2) and later bi-weekly at 12, 15, and 18 mg/m(2). The maximum to...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Weiss, Glen J., Chao, Joseph, Neidhart, Jeffrey D., Ramanathan, Ramesh K., Bassett, Dawn, Neidhart, James A., Choi, Chung Hang J., Chow, Warren, Chung, Vincent, Forman, Stephen J., Garmey, Edward, Hwang, Jungyeon, Kalinoski, D. Lynn, Koczywas, Marianna, Longmate, Jeffrey, Melton, Roger J., Morgan, Robert, Oliver, Jamie, Peterkin, Joanna J., Ryan, John L., Schluep, Thomas, Synold, Timothy W., Twardowski, Przemyslaw, Davis, Mark E., Yen, Yun
Формат: Artigo
Язык:Inglês
Опубликовано: 2013
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3774600/
https://ncbi.nlm.nih.gov/pubmed/23397498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9921-8
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы